Uncategorized

2025 was a year of meaningful progress for Ankerias. We moved from concept to real-world validation and built the first MVP modules of our clinical software platform to support monitoring and clinical decision support in complex neuropathic pain care.

In 2025, we successfully completed a Business Finland Tempo project, strengthening our validation roadmap and sharpening our go-to-market direction. Alongside this, we built and tested the first MVP modules of our clinical software platform to support monitoring and clinical decision support in complex neuropathic pain and SCS therapy.

As part of our clinical development work, we conducted multiple surveys and early-stage pilots during the year. The most significant of these was carried out in collaboration with OuluHealth Labs and provided key insights to support product development and further validation. We also strengthened our research and development collaboration with the University of Oulu and expanded our network.

In 2025, the Ankerias core team strengthened and our expert network expanded. Product development and validation have been advanced through close collaboration across the team, advisors, and clinical and research partners.

In the second half of the year, we advanced our pre-seed round significantly and secured strong investor commitments. We expect to finalize the round in early 2027, and there is still room for additional investors to join.

In 2026, our focus is to expand pilots in Europe, strengthen clinical adoption, and continue developing the platform step by step. We are also working toward first sales in the second half of the year.

More information:
Hanna Viisanen-Kuopila, Founder, CEO hanna@ankerias.com